These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 24398856)

  • 1. Bone-targeting agents in prostate cancer.
    Suzman DL; Boikos SA; Carducci MA
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
    Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
    Wan X; Corn PG; Yang J; Palanisamy N; Starbuck MW; Efstathiou E; Li Ning Tapia EM; Zurita AJ; Aparicio A; Ravoori MK; Vazquez ES; Robinson DR; Wu YM; Cao X; Iyer MK; McKeehan W; Kundra V; Wang F; Troncoso P; Chinnaiyan AM; Logothetis CJ; Navone NM
    Sci Transl Med; 2014 Sep; 6(252):252ra122. PubMed ID: 25186177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
    Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-targeted approach to treating bone metastases.
    Camacho DF; Pienta KJ
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):545-53. PubMed ID: 24390423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer.
    Zhang X
    Cancer Commun (Lond); 2019 Nov; 39(1):76. PubMed ID: 31753020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting bone physiology for the treatment of metastatic prostate cancer.
    Autio KA; Morris MJ
    Clin Adv Hematol Oncol; 2013 Mar; 11(3):134-43. PubMed ID: 23598981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases.
    Whang YM; Jung SP; Kim MK; Chang IH; Park SI
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.
    Turner CJ; Edwards CM
    Curr Osteoporos Rep; 2016 Oct; 14(5):170-7. PubMed ID: 27566487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone metabolism and new targets for intervention.
    Akduman B; Crawford ED
    Curr Urol Rep; 2007 May; 8(3):233-8. PubMed ID: 17459273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone targeted therapies in metastatic castration-resistant prostate cancer.
    Rajpar S; Fizazi K
    Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.
    Som A; Tu SM; Liu J; Wang X; Qiao W; Logothetis C; Corn PG
    Br J Cancer; 2012 Oct; 107(9):1547-53. PubMed ID: 23033003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapies for metastatic castrate-resistant prostate cancer.
    Dayyani F; Gallick GE; Logothetis CJ; Corn PG
    J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
    Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
    J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in bone-targeted therapies of metastatic prostate cancer.
    Deng X; He G; Liu J; Luo F; Peng X; Tang S; Gao Z; Lin Q; Keller JM; Yang T; Keller ET
    Cancer Treat Rev; 2014 Jul; 40(6):730-8. PubMed ID: 24767837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
    Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
    Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer.
    Msaouel P; Galeas JN; Boiles AR; Ruiz RR; Koutsilieris M
    Curr Drug Targets; 2016; 17(3):276-89. PubMed ID: 25892311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal-related events in prostate cancer.
    Smith MR
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):535-6. PubMed ID: 23073052
    [No Abstract]   [Full Text] [Related]  

  • 20. The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis.
    Suominen MI; Wilson T; Käkönen SM; Scholz A
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31405099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.